TMO
Thermo Fisher Scientific Inc.
Stock
$675.05−4.56 (−0.67%)Close Sep 30, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.0B | $7.8B | $8.7B | $8.4B | $9.2B | $9.3B | $8.3B | $5.0B | $4.5B | $4.0B | $3.3B | $2.9B | $2.6B | $2.0B | $2.0B | $1.7B | $1.5B | $1.7B | $1.4B | $1.5B |
| Capital expenditures | $1.7B | $1.5B | $1.4B | $1.5B | $2.2B | $2.5B | $1.5B | $926M | $758M | $508M | $444M | $423M | $428M | $282M | $315M | $261M | $245M | $200M | $264M | $176M |
| Free cash flow | $7.3B | $6.3B | $7.3B | $6.9B | $6.9B | $6.8B | $6.8B | $4.0B | $3.8B | $3.5B | $2.8B | $2.5B | $2.2B | $1.7B | $1.7B | $1.4B | $1.3B | $1.5B | $1.2B | $1.3B |
| Stock-based compensation | $319M | $310M | $301M | $278M | $307M | $230M | $196M | $181M | $181M | $159M | $133M | $125M | $117M | $91M | $78M | $80M | $82M | $67M | $57M | $51M |
| Buybacks | $5.0B | $3.0B | $4.0B | $3.0B | $3.0B | $2.0B | $1.5B | $1.5B | $500M | $750M | $1.3B | $500M | $0 | $90M | $1.2B | $1.3B | $1.0B | $415M | $187M | $898M |
| Dividends paid | $662M | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | $237M | $238M | $241M | $235M | $216M | $142M | $0 | — | — | — | — |
| Dividends per share | $1.80 | $1.72 | $1.56 | $1.40 | $1.20 | $1.04 | $0.88 | $0.76 | $0.68 | $0.60 | $0.60 | $0.60 | $0.60 | $0.60 | $0.54 | $0.00 | $0.00 | — | — | — |
| Free cash flow margin | 15.8% | 14.1% | 16.9% | 16.2% | 15.4% | 17.3% | 21.2% | 15.8% | 15.5% | 16.7% | 15.4% | 14.8% | 13.0% | 13.2% | 13.8% | 12.4% | 12.1% | 14.7% | 11.0% | 13.4% |